ST. PAUL, Minn., July 20, 2017 /PRNewswire/ -- EnteroMedics
Inc. (NASDAQ:ETRM), a developer of minimally invasive medical
devices to treat obesity, metabolic diseases and other
gastrointestinal disorders, today announced the receipt of a
European Patent Certificate. The Company was granted Patent
number 2254659 titled "Treatment of excess weight by neural
downregulation in combination with compositions." The patent
pertains to EU protection of a system for combination therapy and
corresponds with the Company's US intellectual property.
"As we develop our platform approach for the durable treatment
of obesity, we are in parallel, continuing to strengthen our
intellectual property portfolio which supports our proprietary
technologies, methodologies and therapies," said Dan Gladney, EnteroMedics' President, Chief
Executive Officer, and Chairman of the Board. "We are pleased
to have been granted the '659 patent as a continuation of these
efforts."
Information about the vBloc® System and vBloc® Neurometabolic
Therapy
You should not have an implanted vBloc System if you have
cirrhosis of the liver, high blood pressure in the veins of the
liver, enlarged veins in your esophagus or a significant hiatal
hernia of the stomach; if you need magnetic resonance imaging
(MRI); if you have a permanently implanted, electrical medical
device; or if you need a diathermy procedure using heat. The most
common related adverse events that were experienced during clinical
study of the vBloc System included pain, heartburn, nausea,
difficulty swallowing, belching, wound redness or irritation, and
constipation.
Talk with your doctor about the full risks and benefits of vBloc
Neurometabolic Therapy and the vBloc System. For additional
prescribing information, please visit www.enteromedics.com.
If you are interested in learning more about vBloc Therapy,
please visit www.vbloc.com or call 1-800-MY-VBLOC.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the
development and commercialization of technology to treat obesity
and metabolic diseases. vBloc® Neurometabolic Therapy, delivered by
an FDA-approved pacemaker-like device called the vBloc® System, is
designed to help patients feel full and eat less by intermittently
blocking hunger signals on the vagus nerve. EnteroMedics recently
acquired the Gastric Vest System™ through its acquisition of
BarioSurg, Inc. The Gastric Vest is an investigational, minimally
invasive, laparoscopically implanted medical device being studied
for weight loss in morbidly obese patients. The device wraps around
the stomach, emulating the effect of conventional weight-loss
surgery, and enables gastric volume reduction without permanently
changing patient anatomy.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements generally can be identified
by the use of words such as expect," "plan," "anticipate," "could,"
"may," "intend," "will," "continue," "future," other words of
similar meaning and the use of future dates. These forward-looking
statements are based on the current expectations of our management
and involve known and unknown risks and uncertainties that may
cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others: our
limited history of operations; our losses since inception and for
the foreseeable future; our limited commercial sales experience
with our vBloc® System for the treatment of obesity in the United States or in any foreign market
other than Australia and the
European Community; the competitive industry in which we operate;
our ability to maintain compliance with the Nasdaq continued
listing requirements; our ability to commercialize our vBloc®
System; our dependence on third parties to initiate and perform our
clinical trials; the need to obtain regulatory approval for any
modifications to our vBloc® System; physician adoption of our
vBloc® System and vBloc® Neurometabolic Therapy; our ability to
obtain third party coding, coverage or payment levels; ongoing
regulatory compliance; our dependence on third party manufacturers
and suppliers; the successful development of our sales and
marketing capabilities; our ability to raise additional capital
when needed; international commercialization and operation; our
ability to attract and retain management and other personnel and to
manage our growth effectively; potential product liability claims;
the cost and management time of operating a public company;
potential healthcare fraud and abuse claims; healthcare legislative
reform; and our ability to obtain and maintain intellectual
property protection for our technology and products. These and
additional risks and uncertainties are described more fully in the
Company's filings with the Securities and Exchange Commission,
particularly those factors identified as "risk factors" in the
annual report on Form 10-K filed March 8,
2017 and quarterly report on Form 10-Q filed May 15, 2017. We are providing this information
as of the date of this press release and do not undertake any
obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
otherwise.
View original content with
multimedia:http://www.prnewswire.com/news-releases/enteromedics-announces-receipt-of-european-patent-certificate-300491242.html
SOURCE EnteroMedics Inc.
